Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

A user is seeking advice on purchasing RU58841 from Biolab Shop in Poland and is looking for trustworthy sources that deliver to Germany from Europe or China. They are interested in the product's composition and user experiences.

A 43-year-old male with advanced hair loss is experimenting with alternative treatments, including red light therapy, microneedling, scalp massages, an oil mix, and ketoconazole shampoo, after previously experiencing side effects from finasteride and minoxidil. He noticed some minor changes with red light therapy but remains skeptical about significant improvement.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

The conversation is about obtaining topical tretinoin in Canada for hair loss treatment. Tretinoin is discussed for its ability to increase the absorption of minoxidil.

The conversation is about hair loss treatments. The user considers using a foam with Saw palmetto, caffeine, and EGCG, but another user suggests just using finasteride.

The user has been using Finasteride for seven months to address hair loss but hasn't seen noticeable regrowth and is experiencing brittle, thinning hair with scalp issues. They are also using Salisia and Re’equil Salicylic Acid shampoo for potential psoriasis and are seeking advice from others with similar experiences.

Using dutasteride anally as a hair loss treatment, with humorous and satirical comments on its effects and implications.

RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

The conversation discusses using nandrolone decanoate as a replacement for testosterone to potentially regrow hair, with OP considering stopping finasteride and testosterone replacement therapy (TRT) to try nandrolone solo. Concerns include maintaining estradiol levels, and some users report mixed results with hair regrowth using this approach.

A user experienced side effects from finasteride and switched to using GHK-Cu for hairline improvement, noticing some positive changes after three months. They used a 2mg daily dose via subcutaneous injections and reported increased hair density and baby hairs, though results were not dramatic.

Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

The conversation discusses creating a foam version of RU58841 for easier application on thick hair, comparing it to minoxidil foam. The user currently uses dutasteride, minoxidil, and needling for hair loss treatment.

The conversation discusses attending a presentation by Pelage at the Academy of Dermatology Annual Meeting in Denver, focusing on hair loss treatments. Participants express interest in obtaining information or trial compounds related to hair loss solutions like Minoxidil, finasteride, and RU58841.

The user shares their hair loss regimen, which includes 2.5 mg daily of dutasteride, topical minoxidil with RU58841, and recently added oral minoxidil. They report no side effects and seek feedback from others with similar experiences.

Some hair loss may be linked to chromosome 20, which isn't affected by DHT blockers like finasteride. Treatments like minoxidil, microneedling, and genetic testing are suggested, but their effectiveness for this type of hair loss is uncertain.

The conversation is about hair loss and the effectiveness of treatments like finasteride, with one user expressing satisfaction after seeing hair regrowth on CCTV. Other users share their experiences with hair visibility and discuss the effectiveness of finasteride compared to dutasteride.

RU58841 and topical GHK-CU are used together for hair loss, with RU58841 reducing shedding and GHK-CU improving scalp health. Users report noticeable hair growth and improved hair quality within weeks, especially when used consistently.

OP switched from Finasteride to Dutasteride and experienced continuous hair shedding after 7 months but noticed no reduction in hair density. Other users advised patience, noting similar experiences and eventual hair improvement.

The user has been using finasteride 1 mg daily for 6 months, seeing improvement in hairline but noticing a strange wide part on the side of the crown. Suggestions include using topical dutasteride and considering a hair transplant if the issue persists.

The conversation discusses using Rogaine (Minoxidil) and ketoconazole for hair regrowth, with interest in trying a formulation with Azelaic Acid for potentially better results. Concerns about Azelaic Acid's effectiveness and safety, including skin sensitivity to sunburn, are mentioned.

The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.

The user experienced significant hair regrowth on the crown after 9 months of using oral finasteride and minoxidil, with no side effects. They switched from topical to oral treatments for better results and recommend using a DHT blocker like finasteride for androgenic alopecia.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

The user has been using finasteride for 7 months, minoxidil for 10 months, and dutasteride for 4 months with minimal results and is considering stopping treatment. Replies suggest continuing treatment, adding microneedling, and checking DHT levels.

The user has been using oral finasteride for 15 months and oral minoxidil for 6 months, and developed alopecia areata, for which a dermatologist prescribed calcipotriol/betamethasone. The treatment is helping, but the user is experiencing another shedding phase and is concerned about the effects of the steroid cream and the cause of hair loss.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

GHK-Cu injections led to unexpected temple hair growth for someone who had been using minoxidil and finasteride for over a decade. The user plans to continue using GHK-Cu and experiment with a DIY AHK-Cu serum.